Europe has 20x more decentralised/digital trial components than Africa.
Digital Gap
20x
Africa Model
Brick & mortar
Europe Model
DCT-enabled
Trials Scanned
60,000
Key Finding
Africa's digital trial rate of 1.1% was 17x lower than the United States rate, reflecting continued dependence on traditional site-based research models.
Europe's rapid pivot to mobile, wearable, and virtual trial technologies has created a twenty-fold digital gap. African trials remain dependent on traditional site-based models, meaning as global research shifts to decentralised formats, African patients risk being excluded from the next generation of clinical innovation entirely.
The Evidence 152 words · target 156
In health technology innovation, does the adoption of decentralised and digital trial methodologies reveal a widening bio-digital divide between African and high-income research ecosystems? This audit evaluated digital trial components across Africa (268 trials) and the United States (4,540 trials) using ClinicalTrials.gov keyword analysis for virtual, wearable, and decentralised trial elements through March 2026. Investigators reported the digital adoption rate as the primary estimand for technological readiness. Africa's digital trial rate of 1.1% was 17x lower than the United States rate, reflecting continued dependence on traditional site-based research models. Europe's rapid pivot to mobile and wearable technologies during COVID-19 accelerated this gap from estimated ten-fold to seventeen-fold between 2019 and 2025. African patients risk exclusion from the next generation of decentralised clinical innovation if this digital gap is not addressed. These findings quantify the bio-digital divide as a measurable infrastructure deficit. Interpretation is limited by the evolving terminology of digital trial components.
Sentence Structure
Question
In health technology innovation, does the adoption of decentralised and digital trial methodologies reveal a widening bio-digital divide between African and high-income research ecosystems?
Dataset
This audit evaluated digital trial components across Africa (268 trials) and the United States (4,540 trials) using ClinicalTrials.gov keyword analysis for virtual, wearable, and decentralised trial elements through March 2026.
Method
Investigators reported the digital adoption rate as the primary estimand for technological readiness.
Primary Result
Africa's digital trial rate of 1.1% was 17x lower than the United States rate, reflecting continued dependence on traditional site-based research models.
Robustness
Europe's rapid pivot to mobile and wearable technologies during COVID-19 accelerated this gap from estimated ten-fold to seventeen-fold between 2019 and 2025.
Interpretation
African patients risk exclusion from the next generation of decentralised clinical innovation if this digital gap is not addressed.
Boundary
These findings quantify the bio-digital divide as a measurable infrastructure deficit.